Identification and Characterization of a New Autoimmune Protein in Membranous Nephropathy by Immunoscreening of a Renal cDNA Library

Fabrizio Cavazzini1,9, Riccardo Magistroni1,9, Luciana Furi2, Valentina Lupo1, Giulia Ligabue1, Maria Granito1, Marco Leonelli2, Alberto Albertazzi1, Gianni Cappelli1

1 Department of Medicines, Emergency Medicine and Medical Specialties, Division of Nephrology Dialysis and Renal Transplantation, University of Modena and Reggio Emilia, Modena, Italy, 2 Division of Nephrology Dialysis and Renal Transplantation, Modena University Hospital, Modena, Italy

Abstract

Membranous Nephropathy (MN) represents a large amount of Nephrotic Syndromes in the adult population and its definitive diagnosis is currently carried out through biopsy. An autoimmune condition has been demonstrated in idiopathic MN (iMN) in which some kidney structures are targeted by patient autoantibodies. Some candidate antigens have been described and other likely involved target proteins responsible for the disease are not known yet. In this work our aim is to identify these proteins by screening a lambda-phae library with patients' sera. We enrolled four groups of patients: two MN groups of 12 full iMN patients; one control group of 15 patients suffering from other renal diseases; one control group of 15 healthy individuals. A commercial cDNA phagemide library was screened using the above described sera, in order to detect positive signals due to antigen-antibody bond. We detected one phagemide clone expressing a protein which was shown to be targeted by the antibodies of the iMN sera only. Control sera were negative. The sequence analysis of cDNA matched the Synaptonemal Complex protein 65 (SC65) coding sequence. Further proteomic analyses were carried out to validate our results. We provide evidence of an involvement of SC65 protein as an autoimmune target in iMN. Considering the invasiveness and the resulting risk coming from renal biopsy, our ongoing aim is to set a procedure able to diagnose affected patients through a little- or non-invasive method such as blood sampling rather than biopsy.

Citation: Cavazzini F, Magistroni R, Furi L, Lupo V, Ligabue G, et al. (2012) Identification and Characterization of a New Autoimmune Protein in Membranous Nephropathy by Immunoscreening of a Renal cDNA Library. PLoS ONE 7(11): e48845. doi:10.1371/journal.pone.0048845

Introduction

Membranous Nephropathy (MN) is the most common cause of nephrotic syndrome in adults [1,2]; it can be secondary to other clinical conditions including infections, autoimmune diseases, cancer and some toxic substances or drugs. However in most cases (about 80%), MN is classified as idiopathic (iMN), since the etiology of the nephropathy is still substantially unknown. Although spontaneous remission is observed in about one third of subjects, 40% of the patients develop end-stage renal failure after about 10 years. [2,3] In histopathological preparations, a thickening of the glomerular basal membrane is observable as a consequence of subepithelial deposits of immune complexes with immunoglobulins predominantly belonging to the IgG1 subclass. [4,5] Such complexes are apparent in immunofluorescence conducted with anti-IgG antibodies and in electron microscopy as subepithelial electron-dense deposits. A pivotal role in the events causing the glomerular lesions is played by the activation of complement and the assembly on the podocyte surface of the membrane attack complex C5b-9 that may be triggered by the same immunodeposits. [6,7,8].
M-type phospholipase A2 receptor (PLA2R) in about 70% of cases. This glycoprotein is expressed by podocytes and colocalizes with IgG in the subepithelial immune complex deposits. The second group (including the last two papers cited above) found that aldose reductase (AR), manganese superoxide dismutase (SOD2) and enolase (ENO1) are targeted by iMN patients IgG4, thus effectively adding three more targets to the iMN antigen list.

On the basis of evidence of an autoimmune pathogenesis of the disease consisting in autoantibodies directed to primitive renal disease, we consider that NEP, AR, SOD2, ENO1 and PLA2R do not exclude a possible role for other antigens [17], we looked for patients sera reactivity to a wide panel of renal proteins. In particular, we screened a large number of lysis plaques from a lambda phage cDNA expression library comparing MN and control patients sera. Candidates were further validated by immune screenings and immunofluorescence techniques.

Methods

Patients and Control Subjects

Twelve nephrotic patients affected by iMN for the discovery phase and twelve nephrotic patients affected by iMN for the confirmation phase were recruited. The diagnosis of iMN was made on the basis of biopsy examination using immunofluorescence techniques and optical microscopy according to the parameters of the ‘World Health Organization Centre for the Histological Classification of Renal Diseases, 1982’. Patients with the following characteristics were included in this study: biopsy-proven iMN, age older than 18 years, proteinuria >2 g/day, creatinine <1.8 mg/dL. Patients affected by connective-tissue diseases, positive to ANA, ENA antiDNA, antiphospholipids antibodies, ANCA, diabetes mellitus, neoplasia, Hepatitis B or C virus infection, HIV or systemic diseases, patients younger than 18 years at the time of biopsy were excluded.

Clinical data at the time of biopsy included serum creatinine, glomerular filtration rate measured according to the MDRD formula [18], proteinuria (g/24 h), systolic and diastolic blood pressure.

Fifteen nephrotic patients affected by glomerulonephrites other than iMN or secondary MN were recruited (4 with diabetic nephropathy, 4 with focal glomerulosclerosis, 4 with type I membranoproliferative glomerulonephritis, 3 with minimal change disease). Histological diagnosis and collection of clinical data were performed following the same procedures as for the iMN patients. Fifteen normal subjects recruited among blood donors and matched to the iMN patients for age and sex were also recruited.

The samples were assigned numbers to render them anonymous. The institutional review board of our University Hospital approved the study and written informed consent was obtained from all of the subjects.

Kidney Biopsy

Normal renal tissue was obtained by a cadaveric kidney donor. Biopsies from patients recruited for the study were clinically indicated in order to assist with specific diagnosis. Biopsy was performed with a standard technique (see Methods S1).

Immunofluorescence

OCT (Tissue Tek, Miles, Elkhart, IN) was the embedding medium for biopsy sample freezing in liquid nitrogen. Samples were subsequently cut into 3 µm sections by a cryostat (Leica 1720, Leica Microsystems, Heerbrug, Germany) and placed on glass slides (SuperFrost, Gerhard Menzel, Brunswick, Germany) for indirect immunostaining. Cryosections were fixed in modified Carnoy solution for 10 minutes at 4°C and subsequently washed in PBS. Non-specific binding was blocked by incubation in BSA 3% w/v in PBS for 20 minutes at room temperature. Sections were then incubated for 1 hour at 37°C with primary mouse anti-No55 antibody (BD Transduction Laboratories, BD Biosciences, San Jose CA, USA) and mouse anti-human IgG4 (Invitrogen Corporation, Carlsbad CA, USA) or mouse anti-Synaptopodin (Abnova

Table 1. Clinical characteristics of patients.

| Parameter                              | Patient |
|----------------------------------------|---------|
|                                        | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Gender                                 | M M M F M F M M M M F M F F F F F F F F M |
| Age at diagnosis                       | 44,4 77,3 37,7 75,9 63,6 68,5 40,7 49,1 66,4 72,6 88,7 75,1 21,4 69,3 77,1 48 64 70 29,2 85 76 67,6 38,6 50,6 |
| Histologic stage                       | I-II I II-II II-II III I I II-II II-II I III I II III I II III I I-II II-II II |
| Serum creatinine (mg/dl)               | 1,08 1,32 1,33 1,43 0,83 1,23 1,14 0,95 0,88 0,86 1,55 1,5 1,1 2 2 0,6 1,08 1,09 0,52 1 1,7 0,65 0,79 0,88 |
| at diagnosis                           | 1,69 0,87 0,85 1,09 0,92 1,45 1,2 0,86 2,06 1,13 0,66 1,74 |
| after 1 year                           | 2,5 2,42 2,8 2,45 2,74 2,2 2 2,46 2,58 2,83 2,74 2,6 2,81 2,21 1,7 2,5 3,7 2,88 3,35 2,3 2,2 2,9 3,29 3,05 |
| Serum albumin                          | 4,3 4,53 3,99 2,77 2,53 3,99 3,71 3,58 1,97 4,01 4,42 3,15 |
| at diagnosis                           | 3,5 3 4,8 4,5 3,3 6,61 8 2,28 7,65 8 4,83 6,69 2,55 4,4 4,4 10 5,9 1,2 2,3 11,5 3,9 4,4 4,9 3,5 |
| after 1 year                           | 0,69 0,93 1,38 1,62 0,95 1 2,7 1,9 25 0,1 0 5,3 |
| Proteinuria                            | NA N N N N N N N N N N N N N N N N N N N N N N |
| at diagnosis                           | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| after 1 year                           | ACEI/ARB |

doi:10.1371/journal.pone.0048845.t001
Corporation, Taipei City, Taiwan) diluted 1:10 in blocking solution. Alexa Fluor® 488 goat anti-mouse IgG2a (1:1000) and Alexa Fluor® 568 goat anti-mouse IgG1 (1:1000) (Invitrogen) were used as secondary antibodies. Negative controls were processed in parallel using an equivalent concentration of a normal mouse antiserum as primary antibody.

**Figure 1. Second selection of positive clone.** Many plaques from pickup of first positive signal have developed on another plate. Exogenous proteins produced by single plaques have been adsorbed to this filter membrane, and tested for the immunoreactivity with iMN patient serum. The difference between positive and negative plaques is apparent. doi:10.1371/journal.pone.0048845.g001

**Figure 2. Recombinant spot assay of each serum.** Positively reacting sera are those showing the dark spot in the middle of the membrane, where the recombinant SC65 protein was spotted. doi:10.1371/journal.pone.0048845.g002
Preparation of Patient Sera

A 10 ml blood sample was collected from every subject early in the morning prior to biopsy and before the patient was indicated for immunosuppressive therapy. Within a few minutes from collection, serum was isolated by centrifugation (1000 × g, 7 min) and stored immediately at −75°C. Prior to use, the serum samples were pooled in four groups: (i) from 12 iMN patients (discovery group), (ii) from other 12 iMN patients (confirmation group), (iii) from 15 non-MN renal patients (assorted as described), and (iv) from 15 healthy individuals. Preabsorption membranes were obtained by plating approximately 5,000 plaque forming units (pfu) of lambda phage carrying GAPDH cDNA and *E. coli* XL1-Blue MRF’ strain in NZY top agar and laying nitrocellulose membranes (Purabind 045 by Whatman, Dassel, Germany) previously soaked in 10 mM IPTG and air-dried.

Each serum pool was diluted 1:100 in blocking solution (1× PBS, 3% BSA) and incubated with preabsorption membranes for five times.

Immunoscreening of the cDNA Expression Library

A commercially available 8 pooled kidney cDNA expression library (Stratagene, Cambridge, UK) was immune-screened with sera from the discovery phase group, according to the manufacturer’s protocol.

Positive plaques were re-screened with the same pool of sera to obtain the clonality. Afterwards, phages were recovered as pBluescript plasmids. See Methods S1 for further information.

Serological Spot Assay

Screening of positive clones was carried out by a serological spot assay, as previously described [19]. In brief, 40 μl of exponentially growing *E. coli* XL1-Blue MRF’ were incubated with 40 μl of monoclonal phagemide containing 5,000 pfu per microliter; 0.7 μl of this mixture was spotted on a layer of NZY top agar (0.7% agarose) containing 2.5 mM isopropyl β-D-thiogalactoside laying on a NZY agar Petri plate. Once the mixture was set and the liquid absorbed by agar, a nitrocellulose membrane was laid on the plate and incubated at 37°C overnight. Therefore membranes were washed with TBST, blocked with 1× PBS 3% BSA and incubated overnight with blocking solution containing serum 1:100, previously depleted of lambda phage and *E. coli* XL1-Blue MRF’. On control membranes, a mouse anti-human GAPDH monoclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) diluted 1:4000 was used. Membranes were washed again with TBST and then incubated with sheep anti-human horseradish peroxidase-conjugated IgG antibody (or sheep anti-mouse horseradish peroxidase-conjugated IgG antibody in controls) (GE Healthcare, Little Chalfont, England) diluted 1:4000 in 1× PBS for 1 h. A further cycle of TBST washing was applied. Antigen-
antibody complexes were detected by ECL Western Blotting Detection System (GE Healthcare) and autoradiography film.

Plasmid Excision and Isolation
Clonal plasmids were obtained from phagemids according to the manufacturer’s protocol. See Methods S1 for details. Plasmids were then isolated following small-scale preparation protocol.

Molecular Analyses
Plasmids obtained as described were digested with BdaI and PvuI restriction endonucleases and their inserts amplified for sequencing. See Methods S1 for further details.

Sequencing and Identification
Sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems), and clone inserts were sequenced with an automated sequencer (ABI 3100). Sequence alignment was carried out by searching nucleotide databases with BLAST.

Recombinant Spot Assay
Single sera were tested on spots of commercial recombinant protein SC65 (Abnova, Taipei City, Taiwan). Square 2-cm nitrocellulose membranes were prepared by spotting 0.3 μl of recombinant protein SC65 in the centre and blocked with 3% (w/
BSA in 1× PBS for 1 h. Membranes were incubated overnight in PBS-diluted serum; they were then washed three times in TBST and incubated with sheep anti-human IgG HRP-conjugated antibody 1:4000 in PBS for 1 h. A further cycle of TBST washing was applied. Finally, immunocomplexes were detected by ECL Western Blotting Detection System and autoradiography film.

Cell Culture

A human conditionally immortalized podocyte cell line [20] was cultured and proteins from subcellular fractions were obtained as previously described [7].

**Polyacrylamide Gel Electrophoresis and Western Blotting**

Fifteen μg lanes of subcellular fractions were loaded on a standard 7.5% polyacrylamide gel in order to perform a gel electrophoresis. Migrated proteins were thus electroblotted onto a nitrocellulose membrane to undergo Western blotting analysis using a primary mouse anti-No55 antibody (BD Transduction Laboratories, BD Biosciences, San Jose CA, USA) diluted 1:1000 in blocking solution, and a sheep anti-mouse horseradish peroxidase-conjugated IgG antibody as secondary antibody. The ECL Western Blotting Detection System was used to obtain images on the autoradiography film.

**Results**

**Autoreactive Phagemide Plaque were Identified By Pooled Sera of Patients**

Twenty-four nephrotic patients affected by iMN, 12 patients for the discovery phase and 12 for the confirmation phase were recruited for this work (see the Methods section for details on patient recruitment). The clinical characteristics of these patients are described in Table 1.

In order to identify possible autoreactive immune responses, pooled sera from 12 recruited iMN patients (discovery group) were used to probe a kidney cDNA expression library derived from normal kidney tissue whole mRNA. Sera were obtained at the time point of kidney biopsies, and iMN diagnosis was confirmed by immunofluorescence and histological procedures. Approximately 2×10^12 recombinant clones of the library were screened by the pooled serum.

Six positive clones were detected. Immunoreactive phage plaques were then removed from the corresponding agar plates, and eluted phages were re-plated at lower plaque density and re-screened as above with patients sera to isolate specific, purified phage (Figure 1).

Putatively positive phage plaques were tested through a Serological Spot Assay to confirm the specificity of this immune reactivity. Pooled sera from 12 iMN patients (discovery group), 15 control subjects and 15 patients affected by other glomerulonephritides than MN were used. A strong positive signal for iMN patients was found only from one out of six plaques (arbitrarily coded Q8).

**Q8 Identification by Restriction Fragment Analysis and Sequencing**

After obtaining the pBluescript double stranded phagemid from the Q8 plaque, a restriction analysis using BglII and PvuII endonucleases was performed in order to excide the insert cDNA and estimate its size. Vector double digestion with BglII and PvuII endonucleases led to three fixed-length fragments (325, 1045 and 1158 base pairs) and one fragment whose length is given by cDNA insert plus 397 base pairs from flanking regions. The output of digestion was examined by agarose gel electrophoresis, allowing to infer that the putative length of cDNA fragment is about 2,600 base pairs.

The sequence analysis of the cDNA insert was performed by searching matches in the GenBank database through the BLAST algorithm. The search output pointed to a full identity with coding sequence of Synaptophthalmal Complex protein SC65 (accession number NM_006455), also known as Nucleolar Autoantigen (No55). The cDNA length in Genbank entry is 2619 bp, and the result is consistent with restriction analysis output. The identification was confirmed by the assessment of phagemid plaques expressing SC65 with monoclonal anti-No55 antibody.

**Recombinant Spot Assay**

Each serum was evaluated with respect to its immunoreactivity to a spot of pure recombinant protein SC65 through an immunological analysis of recombinant protein spots. The sera of 24 iMN patients (control and validation sets), 15 non-MN patients and 15 healthy subjects were tested. Positive reactivity of 8 out of 24 patients suffering from iMN was found. None of the 15 non-MN patients and 15 healthy subjects showed reactivity against pure recombinant protein SC65 (Figure 2).

Considering that the clinical features iMN patients with a positive test showed lower albumin levels and a higher creatinine level, neither of these features reached statistical significance.

**Immunofluorescence**

An indirect immunofluorescence staining of renal specimens using the monoclonal antibody against SC65 was carried out. Two commercial monoclonal antibodies raised against SC65 were tested: one of them resulted ineffective for any technique (data not shown). Thus the focus was particularly placed on the second antibody (see Methods), whose activity is certified for western blotting but not for immunofluorescence techniques. In consideration of these limitations, a significant SC65 signal was found in the glomeruli of patients affected by iMN; this pattern was substantially absent in the glomeruli of control tissue. Costaining with synaptopodin showed that SC65 is expressed in the cytoplasm of podocyte cells (Figure 3). The costaining of SC65 and IgG4 deposits in iMN specimens was also further investigated showing no clear match, but rather a polarized expression of IgG4 in the subepithelial district adjacent to a cytoplasmic expression of SC65 (Figure 4).

**Western Blotting**

SDS-PAGE of cultured podocyte subcellular fractions was performed to find the possible localization of SC65 in the cell (Figure 5). Standard electrophoresis did reveal several bands, particularly in the cytoplasmic fraction, and in the membrane fraction as a double band. This is probably due to a post-translational modification of the protein migrating to the membrane. No band is observable in the nuclear compartment.

**Discussion**

Membranous nephropathy is characterized by an accumulation of immune deposits, mainly of the IgG4 immunoglobulin subclass, on the outer aspect of the glomerular basement membrane. The debate on therapeutic management of patients affected by membranous nephropathy has been a regular theme not yet thoroughly addressed. [21,22,23] Steroids, cytotoxic drugs and anti-CD20 agents showed a significant benefit in selected cohorts of patients, reinforcing the hypothesis of a humoral autoimmune nature of the disease. [5,6,7,10,11,14,15,17,24].
Nevertheless, the need for using such an unspecific therapy clearly provides evidence of an unsatisfactory knowledge of the underlying pathogenetic mechanisms. A more specific concept-driven therapy is thus urgently requested and obviously this cannot leave out the knowledge of the nature of immune deposits. We have conducted a clone library screening in the attempt to discover putative antigens representing the target of this autoimmune process.

Our work has pointed out a new protein as a potential candidate antigen for the iMN, i.e. Human Synaptonemal Complex protein SC65, also known as Nucleolar protein No55. By screening a phage library expressing renal proteins, we found a strong and quite specific reactivity for this antigen in the serum of patients affected by iMN. On the other hand, we could not detect the previously described autoantigens of iMN, probably because of the intrinsic limitations of protein representation in phage libraries. [25]

SC65 is a protein first characterized as an autoantigen in one case of interstitial cystitis (IC) in a patient not suffering from kidney diseases, and it was described as localized in the particulate compartment of the interphase nucleus, with a distribution distinct from that of the nucleolar protein B23. [26]

Even if SC65 identified in the interphase nucleus suggests a role in mitotic processes, an alternative role of this protein in meiosis was also debated: our data do not confirm the nucleolar localization of SC65; rather, we detected it in the non-nuclear compartments through histological evaluation and western blot analysis. SC65 expression was described in several normal human tissues: the highest mRNA expression levels were detected in ovaries, pancreas and prostate, whereas lower levels were retrieved in other tissues. Human renal expression has been demonstrated by Northern Blot analysis with an intermediate intensity between the low expression of the liver and the strong expression of the ovaries, pancreas and prostate. Human renal expression has been demonstrated by Northern Blot analysis with an intermediate intensity between the low expression of the liver and the strong expression of the ovaries, pancreas and prostate. [27] An involvement of this protein has also been shown in patients suffering from prostate cancer as a tumour-associated autoantigen. [27]

Both autoimmune (IC) and cancer (prostate cancer) conditions were systematically investigated and excluded in the cohort of iMN patients recruited for this work. To our knowledge, the protein isolated in this study did not correspond to any candidate iMN antigen previously described. It is not clear which mechanism could drive the delivery of an intracellular protein to the extracellular space for its deposition beneath the glomerular basement membrane. Nonetheless, we cannot rule out a role for intracellular proteins and cryptic epitopes if we consider the possibility of exposition of these antigens after podocyte injury by C5b-9 attack complex. [17] Indeed, our results of immunofluorescence basal patterns suggest a newfangled localization of SC65, opening a parallel debate on the physiological function of this protein in the cell.

Despite the strongly significant serologic results, histological conclusions are not definitive for the lacking of clear subepithelial localization of the antigen. We cannot exclude a technical limit of our immunofluorescence histological analysis because the reagent has not been certified for this purpose. Still, the number of patients showing reactivity to the antigen is relevant and furthermore our data suggest a clinical meaning for this association. Indeed positive patients showed lower albumin and higher creatinine levels. We can speculate that positive patients express a more clinically relevant and aggressive disease, and this hypothesis is under further investigation.

In conclusion, our report describes the finding of anti-SC65 antibodies in patients affected by iMN. The role of this antigen under the diagnostic and prognostic value would be ascertained by an extensive analysis of a large cohort of iMN patients that is already in progress.

Supporting Information

Methods S1. (DOC)

Acknowledgments

The authors are grateful to Professor Moin A. Saleem from the University of Bristol for providing human podocyte cell lines. They also express their appreciation to Mirja Ruutu, Professor of Urology Emerita at the Helsinki University Central Hospital, for her kind help and historical clinical memory. This paper was revised by Professor Davide Mazzi (Chair of English at the Faculty of Medicine and Surgery of the University of Modena and Reggio Emilia) to whom authors are also very grateful.

Author Contributions

Conceived and designed the experiments: FC RM. Performed the experiments: FC VL GL. Analyzed the data: FC MG LF ML GC. Contributed reagents/materials/analysis tools: AA GC. Wrote the paper: FC RM.

References

1. Ponticelli C (2007) Membranous nephropathy. J Nephrol 20: 268–287.
2. Wasserstein AG (1997) Membranous glomerulonephritis. J Am Soc Nephrol 8: 664–674.
3. Glasscock RJ (2003) Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23: 324–332.
4. Imai H, Hamai K, Konatsuda A, Ohtani H, Miura AB (1997) IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 51: 270–276.
5. Noel LH, Auclair J, Robicsek F, Strader DB, Chalasani N, et al. (2012) Liver transplantation in patients with membranous nephropathy. J Hepatol 56: 715–722.
6. Kerjaschki D, Neale TJ (1996) Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heyman nephritis). J Am Soc Nephrol 7: 2518–2526.
7. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, et al. (2010) Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21: 507–519.
8. Adler S, Baker PJ, Pritzl P, Couser WG (1984) Detection of terminal complement components in experimental immune glomerular injury. Kidney Int 26: 830–837.
9. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL (1959) Production of nephritogenic factor in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med 100: 660–664.
10. Kerjaschki D, Farquhar MG (1983) Immunocytochemical localization of the Heymann nephritis antigen (GP530) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157: 667–686.
11. Kerjaschki D, Farquhar MG (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 79: 5557–5561.
12. Bruschi M, Candiano G, Murtas C, Prunotto A, Santucci L, et al. (2009) Patients with primary membranous nephropathy lack auto-antibodies against LDL receptor, the homologue of megalin in human glomeruli. NDT Plus; 3:469–72.
13. Debiec H, Guigonis V, Mougnot B, Haymann JP, Bensam A, et al. (2003) Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutrophil cytoplasmic antibodies: toward new concepts in the pathogenesis of glomerular diseases. J Am Soc Nephrol 14 Suppl 1: S27–S32.
14. Debiec H, Nauta J, Coulet F, van der Burg M, Guignonis V, et al. (2004) Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 364: 1252–1259.
15. Beck LH Jr, Bensam RG, Lambeau G, Beck DM, Powell DW, et al. (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21.
16. Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, et al. (2011) Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alf-a-enolase and borderline antigens. J Proteomics 74: 2006–2017.
17. Ronco P, Debiec H (2009) First Identification of an Antigen in Autoimmune Idiopathic Membranous Nephropathy: Toward Targeted Therapy? Am J Kidney Dis.
18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254.
19. Delunardo F, Comi F, Margotti P, Alessandri C, Priori R, et al. (2006) Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behcet’s disease. Arthritis Res Ther 8: R71.
20. Saleem MA, O’Hare MJ, Reiser J, Coward RJ, Inward CD, et al. (2002) A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630–638.
21. Cameron JS (1982) Membranous nephropathy: the treatment dilemma. Am J Kidney Dis 1: 371–375.
22. Cameron JS (1992) Membranous nephropathy–still a treatment dilemma. N Engl J Med 327: 638–639.
23. Glassock RJ (2004) The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis 44: 562–566.
24. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, et al. (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346: 2053–2060.
25. Willats WG (2002) Phage display: practicalities and prospects. Plant Mol Biol 50: 837–854.
26. Ochs RL, Stein TW Jr, Chan EK, Ruutu M, Tan EM (1996) cDNA cloning and characterization of a novel nucleolar protein. Mol Biol Cell 7: 1015–1024.
27. Fossa A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, et al. (2000) Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer. Br J Cancer 83: 743–749.